Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume
In this study, investigators plan to test whether Immune Checkpoint Inhibitor (ICI) treatment leads to an accelerated progression of atherosclerosis in patients with lung cancer. Atherosclerosis is an immune-mediated inflammatory disease and these same checkpoints being targeted for cancer are critical negative regulators of atherosclerosis in animal and cellular models. Aortic plaque progression will be compared between cases (on ICI) and controls from pre-ICI to post-ICI among patients with non-small cell lung cancer. Groups will be matched for age, cancer type and stage and cardiovascular risk factors. Traditional markers of cardiovascular (CVD) risk and cancer-specific factors (ICI mono- and combination therapy, number of cycles, occurrence of immune-related adverse events, chest radiation, steroid use) will be associated with the change in aortic plaque volume.
Checked against the public recordLast updated Aug 25, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Massachusetts General Hospital
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: Cases: * Subjects with non-small cell lung cancer treated with Immune Checkpoint Inhibitors. * Available contrast enhanced CT scans of the chest both immediately pre-ICI (\< 1 month) and latest follow-up. Controls: * Subjects with non-small cell lung cancer, age, cancer stage and cardiovascular risk factor matched to cases. * Available contrast enhanced CT scan of the chest at two time-points at a similar interval between scans as the cases. Exclusion Criteria: none
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Massachusetts General HospitalBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2022. Always confirm current availability with the study team.